

Special Issue

Mesenchymal Stem Cell Application in Regenerative Medicine: From Mechanisms to Therapeutic Approaches

Message from the Guest Editors

Mesenchymal Stem Cells (MSCs), firstly identified as non-hematopoietic multipotent stem cells with the ability to differentiate into cell types from the three embryonic sheets, are now very well established as source of cells with great therapeutic potential, specifically for tissue regeneration and repair associated-diseases. The therapeutic properties of MSCs have been examined in both preclinical and clinical settings for the treatment of various disorders, including cardiovascular, neurodegenerative, immune, lung, liver, kidney and orthopedics diseases. MSCs are immuno-privileged, and this feature make these cells a useful tool to be applied in the field of cell therapy. In addition, MSCs possess immunomodulatory, trophic, angiogenic and antioxidative properties, and all of these effects appear to be in part mediated by the production of a functional secretome. Indeed, in many in vitro and in vivo disease models, MSC-derived products have been identified as responsible for therapeutic effects. Therefore, it becomes crucial to further characterize and define the mechanisms by which MSCs exert their function.

Guest Editors

Dr. Giovanni Zito

Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione,
Palermo, Italy

Dr. Vitale Miceli

Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione,
Palermo, Italy

Deadline for manuscript submissions

closed (31 January 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/121928

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).